Track LivaNova PLC — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

LivaNova PLC LIVN · Stock Open LivaNova PLC in new tab

69.87 USD
EPS
-3.98
P/B
3.30
ROE
-17.63
Beta
0.94
Target Price
74.55 USD
Loading chart...
Key Metrics
Earnings dateFeb. 24, 2027
EPS-3.98
Book Value21.19
Price to Book3.30
Debt/Equity42.04
% Insiders0.737%
Growth
Revenue Growth0.13%
Earnings Growth-0.18%
Estimates
Forward P/E15.53
Forward EPS4.50
Target Mean Price74.55

DCF valuation

Model fair value for LivaNova PLC (LIVN)
Result
Sign in to run the valuation for LIVN.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
mean target 74.55 USD (low 66.00, high 86.00)
Low 66.00
Mean 74.55
High 86.00
Price 69.87
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

LivaNova PLC Logo LivaNova PLC Analysis (LIVN)

United Kingdom Health Care Official Website Stock

Is LivaNova PLC a good investment? LivaNova PLC (LIVN) is currently trading at 69.87 USD. Market analysts have a consensus price target of 74.55 USD. This suggests a potential upside from current levels.

Earnings Schedule: LivaNova PLC is expected to release its next earnings report on Feb. 24, 2027. The market consensus estimate for Forward EPS is 4.50.

Investor FAQ

Does LivaNova PLC pay a dividend?

No, it does not currently pay a dividend.

What asset class is LivaNova PLC?

LivaNova PLC is classified as a Stock. You can compare it against 3 other assets in the "Related Symbols" list on this page.

When is the next earnings date?

The next earnings date is projected to be Feb. 24, 2027. The company currently has a trailing EPS of -3.98.

Company Profile

LivaNova PLC, a medical technology company, designs, develops, manufactures, markets, and sells products and therapies for neurological and cardiac conditions worldwide. The company operates in two segments, Cardiopulmonary and Neuromodulation. The Cardiopulmonary segment provides cardiopulmonary products, including heart-lung machines, oxygenators, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related accessories. The Neuromodulation segment offers VNS Therapy System, an implantable pulse generator and connective lead that stimulates the vagus nerve; and devices that deliver neuromodulation therapy for treating difficult-to-treat depression and drug-resistant epilepsy. The company serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers. The company sells its medical devices through a combination of direct sales representatives, agents, and independent distributors. LivaNova PLC was incorporated in 2015 and is headquartered in London, the United Kingdom.

Exchange Ticker
NMS (United States) LIVN
FRA (Germany) LIA.F
STU (Germany) LIA.SG
Trades
No dividend information available for this instrument.
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion